The value of cysteinyldopa in the follow-up of disseminated malignant melanoma

Melanoma Research

Volumn 10, Issue 4, 2000, Pages 363-369

  Karnell R ^a   Kagedal B ^b   Lindholm, C ^c   Nilsson, B ^a   Arstrand K ^b   Ringborg, U ^a  

^a KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

^b LINKÖPING UNIVERSITY HOSPITAL   (Sweden)

^c RYHOV COUNTY HOSPITAL   (Sweden)

Author keywords

5 S cysteinyldopa; 6 hydroxy 5 methoxyindole 2 carboxylic acid; Disease progression; Disease regression; Follow up; Melanoma; Tumour markers

Indexed keywords

CARBOXYLIC ACID DERIVATIVE; CYSTEINYLDOPA; INDOLE DERIVATIVE; TUMOR MARKER;

ADULT; AGED; ARTICLE; CANCER CHEMOTHERAPY; CANCER STAGING; DIAGNOSTIC ACCURACY; DISEASE ACTIVITY; DISEASE MARKER; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; MELANOMA; PRIORITY JOURNAL; URINE LEVEL;

ADULT; AGED; AGED, 80 AND OVER; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CYSTEINYLDOPA; DISEASE PROGRESSION; FEMALE; FOLLOW-UP STUDIES; HUMANS; INDOLES; MALE; MELANOMA; MIDDLE AGED; SKIN NEOPLASMS; TUMOR MARKERS, BIOLOGICAL;

EID: 0033812917     PISSN: 09608931     EISSN: None     Source Type: Journal    
DOI: 10.1097/00008390-200008000-00008     Document Type: Article

References (18)

1. Biochemical recorders of malignant melanoma
2. Melanin-related metabolites as markers of melanoma: A review
3. 5 Years' experience of 5-S-cysteinyldopa in melanoma diagnosis
4. Evaluation of the clinical usefulness of measuring urinary excretion of 5-S-cysteinyldopa in melanoma: Ten years' experience of 50 patients
5. Eumelanin-related indolic compounds in the urine of treated melanoma patients
6. High plasma level of a eumelanin precursor, 6-hydroxy-5-methoxyindole-2-carboxylic acid as a prognostic marker for malignant melanoma
7. S100B protein, 5-S-cysteinyldopa and 6-hydroxy-5-methoxyindole-2-carboxylic acid as biochemical markers for survival prognosis in patients with malignant melanoma
8. Determination of 5-S-cysteinyldopa in plasma and urine using a fully automated solid-phase extraction-high-performance liquid chromatographic method for an improvement of specificity and sensitivity of this prognostic marker of malignant melanoma
9. Plasma 5-S-cysteinyldopa differentiates patients with primary and metastatic melanoma from patients with dysplastic nevus syndrome and normal subjects
10. Evaluation of melanin-related metabolites as markers of melanoma progression
11. Prognostic value of serum 5-S-cysteinyldopa for monitoring human metastatic melanoma during immunochemotherapy
12. Automated high-performance liquid chromatographic determination of 5-S-cysteinyl-3,4-dihydroxyphenylalanine in urine
13. Analysis of eumelanin-related indolic compounds in urine by high-performance liquid chromatography with fluorimetric detection
14. The stability of 5-S-cysteinyldopa and 6-hydroxy-5-methoxyindole-2-carboxylic acid in human urine
15. Simultaneous measurement of serum 5-S-cysteinyldopa, circulating intercellular adhesion molecule-1 and soluble interleukin-2 receptor levels in Japanese patients with malignant melanoma
16. Serum levels of sICAM-1 and 5-S-cysteinyldopa as markers of melanoma progression
17. Melanin pigments and melanosomal proteins as differentiation markers unique to normal and neoplastic melanocytes
18. Serum 5-S-cysteinyldopa (5-S-CD) as a marker of melanoma progression